Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Thiazolidinediones398 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A18785 | 26942734 | Dig Dis Sci | Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. | 2016 | Details |
| A18940 | 26858440 | Proc Natl Acad Sci U S A | Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. | 2016 | Details |
| A19001 | 26825546 | Eur J Pharmacol | Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression. | 2016 | Details |
| A19055 | 26797396 | Am J Physiol Gastrointest Liver Physiol | Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. | 2016 | Details |
| A19739 | 26381272 | Diabetes Metab Res Rev | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. | 2015 | Details |
| A19763 | 26367736 | Eur Rev Med Pharmacol Sci | Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. | 2015 | Details |
| A19834 | 26316717 | Drug Des Devel Ther | Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. | 2015 | Details |
| A19891 | 26281317 | Turk J Med Sci | Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH). | 2015 | Details |
| A19984 | 26226097 | Clin Gastroenterol Hepatol | Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. | 2015 | Details |
| A20041 | 26194065 | Cytokine | PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. | 2015 | Details |
| A20055 | 26189925 | Hepatology | Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. | 2015 | Details |
| A20262 | 26057287 | JAMA | Nonalcoholic fatty liver disease: a systematic review. | 2015 | Details |
| A20309 | 26035752 | Int J Mol Sci | Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice. | 2015 | Details |
| A20373 | 26005676 | Hepatobiliary Surg Nutr | Fatty liver disease in diabetes mellitus. | 2015 | Details |
| A20576 | 25875942 | PLoS One | LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). | 2015 | Details |
| A20610 | 25852263 | World J Gastroenterol | Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. | 2015 | Details |
| A20726 | 25774446 | Curr Opin Gastroenterol | Nonalcoholic fatty liver disease: new treatments. | 2015 | Details |
| A20827 | 25708949 | Naunyn Schmiedebergs Arch Pharmacol | Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. | 2015 | Details |
| A20830 | 25708290 | J Gastroenterol | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. | 2015 | Details |
| A20839 | 25701721 | Eur J Pharmacol | Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. | 2015 | Details |
| A20908 | 25649191 | Obes Res Clin Pract | Elevation of branched-chain amino acid levels in diabetes and NAFL and changes with antidiabetic drug treatment. | 2015 | Details |
| A21089 | 25542756 | Eur J Pharmacol | Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. | 2014 | Details |
| A21291 | 25429853 | Aliment Pharmacol Ther | NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. | 2014 | Details |
| A21310 | 25414939 | Postgrad Med | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. | 2014 | Details |
| A21440 | 25317811 | Eur Rev Med Pharmacol Sci | Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH). | 2014 | Details |
| A21508 | 25267322 | Aliment Pharmacol Ther | Review article: the management of paediatric nonalcoholic fatty liver disease. | 2014 | Details |
| A21541 | 25242225 | Cell Metab | Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. | 2014 | Details |
| A21600 | 25195022 | J Chromatogr B Analyt Technol Biomed Life Sci | A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. | 2014 | Details |
| A21705 | 25105443 | Ann Transplant | Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis. | 2014 | Details |
| A21855 | 24997826 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases. | 2014 | Details |
| A22067 | 24843703 | J Diabetes Investig | Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. | 2013 | Details |
| A22122 | 24799988 | World J Hepatol | Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. | 2014 | Details |
| A22253 | 24717764 | Curr Opin Gastroenterol | State of the art: treatment of nonalcoholic steatohepatitis. | 2014 | Details |
| A22315 | 24669954 | Expert Opin Drug Metab Toxicol | Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. | 2014 | Details |
| A22333 | 24653581 | Afr J Tradit Complement Altern Med | Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats. | 2013 | Details |
| A22393 | 24622831 | J Physiol Pharmacol | Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis. | 2014 | Details |
| A22454 | 24558317 | ScientificWorldJournal | Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. | 2014 | Details |
| A22461 | 24550584 | Indian J Pharmacol | Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice. | 2014 | Details |
| A22672 | 24373179 | Diabetes Obes Metab | APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. | 2014 | Details |
| A22676 | 27508182 | J Hepatocell Carcinoma | Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma. | 2014 | Details |
| A22833 | 24275089 | Food Chem Toxicol | Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice. | 2013 | Details |
| A22846 | 24274866 | Clin Liver Dis | The role of medications for the management of patients with NAFLD. | 2013 | Details |
| A22854 | 24251709 | J Gastroenterol Hepatol | Treatment of non-alcoholic fatty liver disease. | 2013 | Details |
| A22871 | 24264040 | Int J Mol Sci | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. | 2013 | Details |
| A22879 | 24259612 | Ann Pharmacother | Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. | 2013 | Details |
| A22921 | 24209497 | Lipids Health Dis | Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies. | 2013 | Details |
| A22925 | 24206433 | Aliment Pharmacol Ther | Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. | 2013 | Details |
| A23019 | 24114819 | Ann Hepatol | Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis. | 2014 | Details |
| A23200 | 23965360 | Endocr J | Rosiglitazone attenuates casein-induced hepatic endoplasmic reticulum stress in Sprague-Dawley rats: a novel model of endoplasmic reticulum stress. | 2013 | Details |
| A23228 | 23939604 | Am Fam Physician | Nonalcoholic fatty liver disease: diagnosis and management. | 2013 | Details |
| A23356 | 23845075 | Curr Diabetes Rev | The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. | 2013 | Details |
| A23381 | 23831119 | J Hepatol | Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. | 2013 | Details |
| A23515 | 23718573 | Aliment Pharmacol Ther | Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. | 2013 | Details |
| A23616 | 23625197 | Curr Diab Rep | The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. | 2013 | Details |
| A23674 | 23576902 | ScientificWorldJournal | Current concepts and management approaches in nonalcoholic fatty liver disease. | 2013 | Details |
| A23726 | 23531105 | Lipids Health Dis | Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective. | 2013 | Details |
| A23904 | 23394096 | Curr Pharm Des | Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. | 2013 | Details |
| A23946 | 23363012 | Ann N Y Acad Sci | Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. | 2013 | Details |
| A23948 | 23359475 | Pharmacotherapy | Pharmacologic therapy for nonalcoholic fatty liver disease in adults. | 2013 | Details |
| A23950 | 23356584 | Liver Int | Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. | 2013 | Details |
| A23979 | 23329465 | Drugs | Nonalcoholic fatty liver disease: current issues and novel treatment approaches. | 2013 | Details |
| A24008 | 23304532 | Int J Hepatol | Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. | 2012 | Details |
| A24135 | 25755455 | J Clin Exp Hepatol | A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. | 2012 | Details |
| A24201 | 23127227 | Clin Exp Pharmacol Physiol | Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. | 2012 | Details |
| A24250 | 23075940 | Curr Opin Clin Nutr Metab Care | Vitamin E and nonalcoholic fatty liver disease. | 2012 | Details |
| A24363 | 22966224 | PPAR Res | Update on pparγ and nonalcoholic Fatty liver disease. | 2012 | Details |
| A24411 | 22927782 | ScientificWorldJournal | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. | 2012 | Details |
| A24561 | 22749137 | J Nutr Biochem | Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. | 2012 | Details |
| A24566 | 22742931 | J Gastroenterol Hepatol | Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma. | 2012 | Details |
| A24599 | 22707355 | Hepatology | Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. | 2012 | Details |
| A24655 | 25755424 | J Clin Exp Hepatol | Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. | 2012 | Details |
| A24674 | 22617751 | Curr Opin Lipidol | Nonalcoholic fatty liver disease and lipids. | 2012 | Details |
| A24756 | 22532295 | Arch Pharm (Weinheim) | Synthesis and evaluation of 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of non-alcoholic fatty liver disease. | 2012 | Details |
| A24757 | 22532269 | Hepatology | Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. | 2012 | Details |
| A24766 | 22521558 | Clin Res Hepatol Gastroenterol | Non-alcoholic fatty liver disease in children. | 2012 | Details |
| A24779 | 22505328 | Hepatology | Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. | 2012 | Details |
| A24836 | 22444524 | Dig Liver Dis | Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. | 2012 | Details |
| A24864 | 22420611 | Clin Sci (Lond) | Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. | 2012 | Details |
| A24915 | 22364184 | J Agric Food Chem | Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways. | 2012 | Details |
| A24928 | 22348670 | Ugeskr Laeger | [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]. | 2012 | Details |
| A24951 | 22326434 | Gastroenterology | Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. | 2012 | Details |
| A24984 | 22278337 | Diabetologia | Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. | 2012 | Details |
| A25086 | 22183689 | Hepatology | Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. | 2012 | Details |
| A25203 | 22096112 | Eur J Endocrinol | Recent advances in cardiovascular aspects of polycystic ovary syndrome. | 2011 | Details |
| A25224 | 22081919 | HPB (Oxford) | Metabolic syndrome and hepatic resection: improving outcome. | 2011 | Details |
| A25238 | 22059955 | Health Technol Assess | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. | 2011 | Details |
| A25246 | 22050199 | Aliment Pharmacol Ther | Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. | 2011 | Details |
| A25305 | 21983273 | Biochim Biophys Acta | Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. | 2011 | Details |
| A25323 | 21956711 | Diabetologia | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. | 2011 | Details |
| A25397 | 21893273 | Gastroenterol Clin North Am | Nonalcoholic fatty liver disease: pharmacologic and surgical options. | 2011 | Details |
| A25499 | 21765869 | Therap Adv Gastroenterol | The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. | 2011 | Details |
| A25510 | 21755261 | Braz J Med Biol Res | Effect of silybin on high-fat-induced fatty liver in rats. | 2011 | Details |
| A25518 | 21748770 | Hepatology | Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. | 2011 | Details |
| A25571 | 21703200 | J Hepatol | The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. | 2011 | Details |
| A25641 | 21612059 | Vnitr Lek | [Steatosis and steatohepatitis in diabetic patient]. | 2011 | Details |
| A25681 | 21556019 | Nat Rev Endocrinol | Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. | 2011 | Details |
| A25683 | 21549113 | Eur J Pharmacol | Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease. | 2011 | Details |
| A25721 | 21507897 | FASEB J | Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. | 2011 | Details |
| A25815 | 21430606 | Pol Arch Med Wewn | Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. | 2011 | Details |
| A25836 | 21412139 | Am J Med Sci | Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. | 2011 | Details |